Mera Pharmaceuticals, Inc.
MRPI · OTC
10/31/2020 | 10/31/2011 | 10/31/2010 | 10/31/2009 | |
|---|---|---|---|---|
| Revenue | $0 | $303 | $289 | $599 |
| % Growth | -100% | 4.8% | -51.8% | – |
| Cost of Goods Sold | $0 | $16 | $46 | $28 |
| Gross Profit | $0 | $286 | $243 | $571 |
| % Margin | – | 94.6% | 84.1% | 95.3% |
| R&D Expenses | $0 | $173 | $265 | $324 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $306 | $187 | $364 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $8 | $342 | $105 |
| Operating Expenses | $0 | $487 | $795 | $793 |
| Operating Income | -$0 | -$201 | -$552 | -$222 |
| % Margin | – | -66.4% | -191% | -37.1% |
| Other Income/Exp. Net | $0 | -$1 | -$5 | -$2 |
| Pre-Tax Income | -$0 | -$202 | -$557 | -$224 |
| Tax Expense | $0 | -$14 | -$19 | -$31 |
| Net Income | -$0 | -$188 | -$538 | -$193 |
| % Margin | – | -62% | -186.2% | -32.2% |
| EPS | 0 | -0 | -0.001 | -0 |
| % Growth | 100% | 60% | -150% | – |
| EPS Diluted | 0 | -0 | -0.001 | -0 |
| Weighted Avg Shares Out | 558 | 547,770 | 547,770 | 547,270 |
| Weighted Avg Shares Out Dil | 557 | 547,770 | 547,770 | 547,270 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $2 |
| Interest Expense | $0 | $6 | $5 | $5 |
| Depreciation & Amortization | $0 | $8 | $28 | $85 |
| EBITDA | $0 | -$188 | -$524 | -$134 |
| % Margin | – | -62% | -181.4% | -22.4% |